×

GE.com has been updated to serve our three go-forward companies.

Please visit these standalone sites for more information

GE Aerospace | GE Vernova | GE HealthCare 

header-image
Investor Day

GE HealthCare’s Investor Day Marks New Era of Growth and Innovation as Company Prepares to Spin Off from GE

Peter C. Beller
December 08, 2022

Striking out on one’s own while working as a team may seem like contradictory ideas, but GE HealthCare President and CEO Peter Arduini made it clear that both themes will guide the company’s future after it spins out of parent company GE early next year. The occasion for his remarks was GE HealthCare’s Investor Day at Nasdaq in New York City.

header-image
Healthcare

The Big Picture: GE Healthcare’s Latest Acquisition Could Help Open A New Chapter In Precision Health

Tomas Kellner
May 28, 2021

Julia Casey is a biochemical engineer by training, but she is also a deal-maker at heart. “I like doing deals,” says Casey, who serves as general manager of GE Healthcare’s Pharmaceutical Diagnostics Molecular Imaging business. “I like dealing with startups and thinking how we can leverage their skills and bring them in so we can really see the benefits of everything they’ve done, and the market and the patients can see the benefits of everything they’ve done.”

Press Release

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

October 09, 2019
  • Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment.
  • The two companies will leverage their combined scientific, commercial and market access expertise to work towards a commercial launch.

Chalfont St Giles, UK – October 9th 2019 – GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent.

For media inquiries, please contact:

David Morris
Communications Director, Pharmaceutical Diagnostics
GE Healthcare
+44 7920591370
[email protected]
Europe/London
business unit
tags
Subscribe to pharmaceutical diagnostics